Review





Similar Products

low dose il7  (R&D Systems)
98
R&D Systems low dose il7
Low Dose Il7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low dose il7/product/R&D Systems
Average 98 stars, based on 1 article reviews
low dose il7 - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
low-dose il-2 aldesleukin  (Clinigen Inc)
90
Clinigen Inc low-dose il-2 aldesleukin
Low Dose Il 2 Aldesleukin, supplied by Clinigen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2 aldesleukin/product/Clinigen Inc
Average 90 stars, based on 1 article reviews
low-dose il-2 aldesleukin - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (Thermo Fisher)
90
Thermo Fisher low-dose il-2
Low Dose Il 2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (PeproTech)
90
PeproTech low-dose il-2
Low Dose Il 2, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/PeproTech
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low dose rh il-2  (R&D Systems)
90
R&D Systems low dose rh il-2
Low Dose Rh Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low dose rh il-2/product/R&D Systems
Average 90 stars, based on 1 article reviews
low dose rh il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (Biohaven Pharmaceuticals)
90
Biohaven Pharmaceuticals low-dose il-2
Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use <t>of</t> <t>IL-2</t> and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.
Low Dose Il 2, supplied by Biohaven Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/Biohaven Pharmaceuticals
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2 aldesleukin  (Novartis)
90
Novartis low-dose il-2 aldesleukin
Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use <t>of</t> <t>IL-2</t> and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.
Low Dose Il 2 Aldesleukin, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2 aldesleukin/product/Novartis
Average 90 stars, based on 1 article reviews
low-dose il-2 aldesleukin - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il- 2 cyt- 370  (ProSpec)
90
ProSpec low-dose il- 2 cyt- 370
Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use <t>of</t> <t>IL-2</t> and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.
Low Dose Il 2 Cyt 370, supplied by ProSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il- 2 cyt- 370/product/ProSpec
Average 90 stars, based on 1 article reviews
low-dose il- 2 cyt- 370 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use of IL-2 and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.

Journal: International Journal of Molecular Sciences

Article Title: Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond

doi: 10.3390/ijms24010204

Figure Lengend Snippet: Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use of IL-2 and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.

Article Snippet: I/II , Biohaven Pharmaceuticals , Autologous memory-like NK cells with BHV-1100 (antibody recruiting molecule) and low-dose IL-2 , MM , NCT04634435.

Techniques: Ligand Binding Assay